To appraise the clinical and cost effectiveness of encorafenib in combination with binimetinib within its marketing authorisation for treating advanced unresectable or metastatic BRAF V600 mutation-positive melanoma.
Status In progress
Process STA pre-2018
ID number 923

Provisional Schedule

Committee meeting: 1 15 November 2018
Committee meeting: 2 07 February 2019
Expected publication 25 April 2019

Project Team

Project lead Thomas Feist

Email enquiries


Key events during the development of the guidance:

Date Update
21 June 2018 Invitation to participate
10 May 2018 As you will be aware the Department for Health and Social Care has asked NICE to carry out a Single Technology Appraisal of encorafenib in combination with binimetinib for treating advanced (unresectable or metastatic) BRAF V600 mutation-positive melanoma. Following on from advice received from the company, the appraisal is now expected to start in approximately mid June 2018 when we will write to you about how you can get involved. The deadline for submissions is expected in approximately mid August 2018.
04 April 2018 In progress, In progress
22 September 2017 - 20 October 2017 Consultation on suggested remit, draft scope and provisional matrix of consultees and commentators
05 December 2016 Referral

For further information on how we develop guidance, please see our page about NICE technology appraisal guidance